Juan Antonio R. M.
- Country
- Spain
- Department
- HOSPITAL SAN PEDRO DE ALCANTARA
Research Overview
- Phase 2b/3 Randomized Double‑Blind Placebo‑Controlled Trial of Lunsekimig in Adults with Inadequately Controlled Eosinophilic COPD
- Long-term Safety and Tolerability Evaluation of Itepekimab in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease
- Efficacy and Safety Evaluation of Astegolimab in Chronic Obstructive Pulmonary Disease: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study
Data & Insights
Has run more than one trial at 91 of 303 partner sites.
Specializations
Breast Cancer and Hormone Receptor-Directed Therapy
Clinical research activity includes early breast cancer, metastatic breast cancer, and HER2-positive, HER2-negative, and HR+/HER2- disease. The investigator is involved in studies centered on endocrine therapy, CDK4/6 inhibitors, PI3K pathway targeting, and antibody-drug conjugates.
- HER2-positive breast cancer
- HR-positive / HER2-negative breast cancer
- PIK3CA-mutated breast cancer
- Endocrine-based treatment
- Neoadjuvant and adjuvant breast cancer care
Research also extends to triple-negative breast cancer, BRCA-mutated disease, and recurrence-focused strategies in both operable and advanced settings.
Hematologic Malignancies and Bone Marrow Disorders
The investigator is active in acute myeloid leukemia, myelodysplastic syndromes, multiple myeloma, and lymphoma. The therapeutic landscape includes relapsed/refractory disease, measurable residual disease, and treatment approaches for patients with limited standard options.
- Acute myeloid leukemia and acute leukemia
- Myelodysplastic syndromes and myelofibrosis
- Multiple myeloma
- Diffuse large B-cell lymphoma and follicular lymphoma
- Relapsed/refractory hematologic disease
Additional interests include targeted therapies, immunotherapy, and cellular and antibody-based approaches across malignant blood disorders.
Urologic, Gynecologic, and Melanoma Oncology
Trial involvement covers prostate cancer, bladder cancer, renal cell carcinoma, ovarian cancer, and melanoma. The focus includes disease control in advanced and recurrent settings, perioperative treatment, and recurrence prevention.
- Prostate cancer
- Bladder cancer
- Ovarian cancer
- Renal cell carcinoma
- Melanoma
Research activity also includes immune-based and targeted oncologic treatments for solid tumors with high-risk or metastatic features.
Cardiovascular Disease and Thrombotic Risk
The investigator participates in studies on coronary artery disease, atherosclerotic cardiovascular disease, spontaneous coronary artery dissection, and aortic valve stenosis. The therapeutic scope includes prevention of major cardiovascular events and management of vascular risk.
- Coronary artery disease
- Spontaneous coronary artery dissection
- Atherosclerotic cardiovascular disease
- Cardiovascular prevention
- Genetic cardiomyopathy risk
Research also includes antiplatelet therapy, lipid-lowering strategies, and management of patients with elevated cardiovascular risk profiles.
Respiratory, Hepatic, and Immune-Mediated Conditions
Clinical interests further extend to chronic obstructive pulmonary disease, eosinophilic asthma, chronic hepatitis B, and drug-induced liver injury. The investigator is also involved in immune-mediated disorders such as immune thrombocytopenia, paroxysmal nocturnal hemoglobinuria, and IgA nephropathy.
- Chronic obstructive pulmonary disease
- Eosinophilic asthma
- Chronic hepatitis B
- Drug-induced liver injury
- Immune-mediated hematologic and renal disease
These areas reflect involvement in anti-inflammatory, antiviral, and supportive care therapeutic domains.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.